

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

tofacitinib 22 mg Extended Release (Xeljanz XR 22 mg)

Notes:

- Quantity Limits: Yes
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **tofacitinib 22 mg extended release (Xeljanz XR 22 mg)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a gastroenterologist
- Patient has a diagnosis of ulcerative colitis
- Patient has tried and failed/intolerant to at least 1 of the following
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)
- Patient has had previous trial of tofacitinib immediate release (10 mg twice daily) with documented concerns about adherence to twice daily dosing
- Patient is not currently taking any other medications dosed more than one time a day

Criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously:

- Prescriber is a gastroenterologist
- Patient has a diagnosis of ulcerative colitis
- Patient has had previous trial of tofacitinib immediate release (10 mg twice daily) with documented concerns about adherence to twice daily dosing
- Patient is not currently taking any other medications dosed more than one time a day